The hytrin community assessment trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia

Benign Prostatic Hyperplasia

“…Treatment achieved significantly greater mean improvement in international prostate symptom score ( − 7.6 points from baseline with terazosin v − 3.7 with placebo; mean change, terazosin v placebo − 3.9 points, 95% confidence interval − 5.5 points to − 3.3 points). 11 We found insufficient evidence on the effect of blockers on complications of BPH. One small RCT found sustained release alfuzosin (5 mg twice daily) for 48 hours increased the ability to pass urine after catheter removal in men catheterised for acute retention, from 5% to 29% (number needed to treat (NNT) 4).…”

α1-Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms

“…6 ± 8 In the VA cooperative trial, patients strati®ed by baseline peak¯ow rate (quartiles: 8. 65, 8.65 ± 10.75, 10.75 ± 12.45, b 12.45 ml/s) responded equally well to an a 1 -adrenoceptor blocker, and there was no relationship between changes in symptom score and ow rate. 7 Thus, patients with LUTS may or may not have obstruction.…”

“…(1996) 65 Fawzy et al (1995) 59 Gillenwater et al (1995) ) 107 Abrams et al (1995) 61 Chapple et al (1996) 108 Lepor et al (1998) 109 Enhanced spinal re¯exes are also present in patients with obstruction and storage symptoms, as demonstrated by the ice-water test that triggers a C ®bre, capsaicinsensitive spinal micturition re¯ex. This re¯ex, which is normally present only in the ®rst few months of life, reoccurs in patients with suprasacral spinal injuries or upper motor neurone disease.…”

Alpha–1–adrenoceptor blockade in the treatment of benign prostatic hyperplasia

“…The total number for terazosin excludes patients from the McKiernan and Lowe survey 57 who are represented in three other terazosin studies). 47,56,59 Study durations were generally longer in terazosin studies (8 ± 52 weeks) than in trials of alfuzosin (12 ± 26 weeks), doxazosin (9 ± 16 weeks), and tamsulosin (4 ± 13 weeks).…”